



**SZABO
SCANDIC**

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic



GAPDH (m6): 293T Lysate: sc-120417



The Power to Question

BACKGROUND

Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), also called uracil DNA glycosylase, catalyzes the reversible oxidative phosphorylation of glyceraldehyde-3-phosphate in the presence of inorganic phosphate and nicotinamide adenine dinucleotide (NAD), an important energy-yielding step in carbohydrate metabolism. While GAPDH has long been recognized as playing an integral role in glycolysis, additional functions of GAPDH include acting as an uracil DNA glycosylase, activating transcription, binding RNA and involvement in nuclear RNA export, DNA replication and DNA repair. Expression of GAPDH is upregulated in liver, lung and prostate cancers. GAPDH translocates to the nucleus during apoptosis. GAPDH complexes with neuronal proteins implicated in human neurodegenerative disorders including the β -Amyloid precursor, Huntingtin and other triplet repeat neuronal disorder proteins.

REFERENCES

1. Meyer-Siegler, K., et al. 1991. A human nuclear uracil DNA glycosylase is the 37 kDa subunit of GAPDH. Proc. Natl. Acad. Sci. USA 88: 8460-8464.
2. Rondinelli, R.H., et al. 1997. Increased GAPDH gene expression in late pathological stage human prostate cancer. Prostate Cancer Prostatic Dis. 2: 66-72.
3. Eyschen, J., et al. 1999. Engineered glycolytic GAPDH binds the anti conformation of NAD⁺ nicotinamide but does not experience A-specific hydride transfer. Arch. Biochem. Biophys. 364: 219-227.
4. Sirover, M.A. 1999. New insights into an old protein: the functional diversity of mammalian GAPDH. Biochim. Biophys. Acta 1432: 159-184.
5. Berry, M.D., et al. 2000. GAPDH and apoptosis. J. Neurosci. Res. 60: 150-154.
6. Tatton, W.G., et al. 2000. GAPDH in neurodegeneration and apoptosis signaling. J. Neural Transm. Suppl. 60: 77-100.
7. Tarbe, N., et al. 2001. Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. Anticancer Res. 5: 3221-3228.
8. Mazzola, J.L., et al. 2002. Alteration of intracellular structure and function of GAPDH: a common phenotype of neurodegenerative disorders? Neurotoxicology 23: 603-609.

CHROMOSOMAL LOCATION

Genetic locus: Gapdh (mouse) mapping to 6 F3.

PRODUCT

GAPDH (m6): 293T Lysate represents a lysate of mouse GAPDH transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

APPLICATIONS

GAPDH (m6): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive GAPDH antibodies. Recommended use: 10-20 μ l per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.